Abivax S.a.
Clinical trials sponsored by Abivax S.a., explained in plain language.
-
New pill shows promise for Long-Term ulcerative colitis control
Disease control OngoingThis study looks at the long-term safety and effectiveness of a daily pill called ABX464 for people with moderate to severe ulcerative colitis. About 200 participants who were already in earlier studies will take the drug for up to 54 months. The goal is to see if the drug can ke…
Phase: PHASE2 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New daily pill aims to keep ulcerative colitis in remission
Disease control OngoingThis study tests a daily medication called ABX464 (25 mg or 50 mg) versus a placebo in over 1,100 people with moderate-to-severe ulcerative colitis. The goal is to see if the drug can safely maintain remission for up to 44 weeks. Participants had already completed an earlier indu…
Phase: PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated May 19, 2026 11:59 UTC